evolocumab Research Reference

Catalog classification, reference sizes, lab math links, and source-backed data. Educational use only — not medical advice.

Researched for: PepTools vendor-neutral scientific reference catalog

PCSK9 inhibitor; human monoclonal antibody; lipid-modifying biologic compound Reference needs_revision Best effort · source review pending

Also known as: Repatha, AMG 145, evolocumabum

Open in Calculator ← Compound Index All Tools

Best-effort research profile: this record has not passed full two-source scientific verification. Descriptive fields, research protocols, storage/handling notes, and interaction guidance below are shown with their evidence labels, but calculator presets and exact dosing math remain hidden until the record is verified or reaches Community-Supported status.

Quick Facts

Reference Sizes

Not standardized / source review pending

Storage

Store refrigerated at 2–8 °C in the original carton to protect from light. Do not freeze or shake. The labeled prefilled pen, autoinjector, or syringe may be stored at 20–25 °C in the original carton for up to 30 days; product stored at room temperature for more than 30 days is to be discarded.

Best-Effort Research Profile

Evolocumab is a fully human immunoglobulin G2-lambda monoclonal antibody directed against human proprotein convertase subtilisin/kexin type 9 (PCSK9). By binding PCSK9, it prevents PCSK9 from promoting hepatic LDL-receptor degradation, increasing LDL-receptor availability and enhancing clearance of circulating LDL cholesterol. Evolocumab is a lipid-modifying biologic administered as a sterile solution by the subcutaneous route.

Source review pending. This descriptive profile is shown from the available source material as a best-effort educational reference. It has not passed the full verification bar and is not a dosing instruction, medical claim, or treatment recommendation.

Research Profile

Half-Life

Estimated effective half-life: 11–17 days.

Onset

Maximum suppression of circulating unbound PCSK9 occurred within 4 hours after a single subcutaneous administration. Maximum LDL-cholesterol reduction occurred by approximately 2 weeks after a 140 mg dose and 3 weeks after a 420 mg dose in the FDA-labeled pharmacology description.

Administration Routes (Research)

subcutaneous

Reported Research Effects

Binds circulating PCSK9.
Blocks PCSK9 interaction with hepatic LDL receptors and reduces LDL-receptor degradation.
Increases hepatic LDL-receptor availability and lowers circulating LDL cholesterol.
Clinical studies report reductions in LDL cholesterol and other atherogenic lipid parameters, including apolipoprotein B and lipoprotein(a).

Reflects preclinical/research literature context only. Not a medical claim, dosing instruction, or treatment recommendation.

Research Notes

Reference clinical regimens described in the FDA label include 140 mg subcutaneously every 2 weeks or 420 mg subcutaneously once monthly for adults with hypercholesterolemia or increased cardiovascular risk and for adults and pediatric patients aged 10 years and older with heterozygous familial hypercholesterolemia. For homozygous familial hypercholesterolemia, the labeled initial regimen is 420 mg subcutaneously once monthly, with an increase to 420 mg every 2 weeks under specified clinical circumstances. These are regulatory and study-reference regimens, not individualized treatment instructions.

Supplementary research context only. Not medical advice or a treatment recommendation.

Registry Identifiers

CAS RN 1256937-27-5; FDA UNII LKC0U3A8NJ; RxNorm RxCUI 1665684; ChEMBL2364655; approximate molecular mass 144 kDa; WHO INN evolocumab

Source-Backed Observations

Evolocumab is a large glycoprotein biologic produced in genetically engineered Chinese hamster ovary cells. The U.S. reference formulation is a clear to opalescent, colorless to pale-yellow, preservative-free solution; the labeled formulation has a pH of 5.0 and contains acetate, polysorbate 80, proline, water for injection, and sodium hydroxide for pH adjustment.

Reflects published research. Educational reference — not a recommendation for use.

Sources Under Review

REPATHA (evolocumab) U.S. Prescribing Information, revised July 2026
https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/125522s049lbl.pdf (accessed 2026-09-03)

REPATHA—evolocumab injection, solution; DailyMed label
https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=cd61e902-166d-4aa6-9f3c-a18c1008d07e (accessed 2026-09-03)

Repatha: EPAR medicine overview
https://www.ema.europa.eu/en/medicines/human/EPAR/repatha (accessed 2026-09-03)

Clinical Pharmacokinetics and Pharmacodynamics of Evolocumab, a PCSK9 Inhibitor
https://pubmed.ncbi.nlm.nih.gov/29353350/ (accessed 2026-09-03)

Evolocumab—PubChem compound record
https://pubchem.ncbi.nlm.nih.gov/compound/Evolocumab (accessed 2026-09-03)

Suggest a community source

Found a relevant Reddit or forum thread about this compound? Suggest it below. Every suggestion is reviewed by an editor before it appears -- nothing is published automatically.

Related Research Tools

Reconstitution CalculatorConcentration, draw volume, per-unit amounts Unit Convertermg, mcg, mL, units conversion Compound CompareSide-by-side comparison tool Cost CalculatorCost per mg, mcg, per-draw

Research Use Only. All content is for educational and research reference only. Not medical advice, a treatment recommendation, or guidance on human use. Compounds are not FDA-approved drugs unless specifically noted.